Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GILD |
---|---|---|
09:32 ET | 96859 | 79.24 |
09:33 ET | 16011 | 79.27 |
09:35 ET | 15252 | 79.15 |
09:37 ET | 9493 | 79.095 |
09:39 ET | 9030 | 79.26 |
09:42 ET | 8376 | 79.37 |
09:44 ET | 18968 | 79.38 |
09:46 ET | 16803 | 79.35 |
09:48 ET | 26506 | 79.25 |
09:50 ET | 12409 | 79.39 |
09:51 ET | 5642 | 79.31 |
09:53 ET | 39470 | 79.31 |
09:55 ET | 17725 | 79.45 |
09:57 ET | 22155 | 79.52 |
10:00 ET | 12646 | 79.595 |
10:02 ET | 17303 | 79.47 |
10:04 ET | 17168 | 79.485 |
10:06 ET | 14997 | 79.55 |
10:08 ET | 26041 | 79.66 |
10:09 ET | 57761 | 79.8175 |
10:11 ET | 65617 | 79.885 |
10:13 ET | 46606 | 79.845 |
10:15 ET | 205401 | 79.98 |
10:18 ET | 17990 | 79.98 |
10:20 ET | 20577 | 79.995 |
10:22 ET | 26769 | 79.995 |
10:24 ET | 30528 | 79.99 |
10:26 ET | 42161 | 80.01 |
10:27 ET | 21309 | 80.07 |
10:29 ET | 29914 | 80.13 |
10:31 ET | 18880 | 80.04 |
10:33 ET | 14311 | 80.045 |
10:36 ET | 26932 | 80.06 |
10:38 ET | 19167 | 80.045 |
10:40 ET | 11552 | 80.015 |
10:42 ET | 13742 | 80.02 |
10:44 ET | 12232 | 80.02 |
10:45 ET | 16767 | 80.01 |
10:47 ET | 16301 | 79.985 |
10:49 ET | 16001 | 79.92 |
10:51 ET | 9309 | 79.77 |
10:54 ET | 22605 | 79.72 |
10:56 ET | 11975 | 79.7 |
10:58 ET | 12886 | 79.71 |
11:00 ET | 7087 | 79.745 |
11:02 ET | 20221 | 79.7 |
11:03 ET | 12563 | 79.805 |
11:05 ET | 13329 | 79.785 |
11:07 ET | 12222 | 79.8 |
11:09 ET | 11030 | 79.73 |
11:12 ET | 11443 | 79.72 |
11:14 ET | 16977 | 79.77 |
11:16 ET | 13436 | 79.77 |
11:18 ET | 14188 | 79.78 |
11:20 ET | 15609 | 79.7098 |
11:21 ET | 16117 | 79.72 |
11:23 ET | 22341 | 79.708 |
11:25 ET | 12848 | 79.72 |
11:27 ET | 17561 | 79.8 |
11:30 ET | 4727 | 79.74 |
11:32 ET | 18076 | 79.7 |
11:34 ET | 27411 | 79.6 |
11:36 ET | 22466 | 79.645 |
11:38 ET | 14386 | 79.585 |
11:39 ET | 16994 | 79.49 |
11:41 ET | 18593 | 79.48 |
11:43 ET | 10417 | 79.475 |
11:45 ET | 8033 | 79.47 |
11:48 ET | 12257 | 79.53 |
11:50 ET | 6967 | 79.59 |
11:52 ET | 6594 | 79.57 |
11:54 ET | 10572 | 79.5611 |
11:56 ET | 19540 | 79.545 |
11:57 ET | 22924 | 79.565 |
11:59 ET | 28816 | 79.515 |
12:01 ET | 9339 | 79.48 |
12:03 ET | 4951 | 79.43 |
12:06 ET | 6750 | 79.47 |
12:08 ET | 5466 | 79.505 |
12:10 ET | 6865 | 79.545 |
12:12 ET | 17096 | 79.5415 |
12:14 ET | 4090 | 79.45 |
12:15 ET | 5716 | 79.42 |
12:17 ET | 18845 | 79.405 |
12:19 ET | 3790 | 79.37 |
12:21 ET | 3595 | 79.335 |
12:24 ET | 9044 | 79.325 |
12:26 ET | 7018 | 79.33 |
12:28 ET | 7611 | 79.33 |
12:30 ET | 7788 | 79.35 |
12:32 ET | 14417 | 79.395 |
12:33 ET | 8025 | 79.36 |
12:35 ET | 6077 | 79.365 |
12:37 ET | 9932 | 79.4 |
12:39 ET | 38393 | 79.36 |
12:42 ET | 6377 | 79.34 |
12:44 ET | 4960 | 79.295 |
12:46 ET | 8466 | 79.23 |
12:48 ET | 34291 | 79.22 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Gilead Sciences Inc | 98.5B | 17.0x | -13.86% |
Amgen Inc | 145.0B | 19.2x | +1.96% |
Bristol-Myers Squibb Co | 102.2B | 12.6x | +4.53% |
GSK plc | 74.8B | 9.7x | +9.56% |
HALEON PLC | 37.7B | 24.2x | --- |
Viatris Inc | 11.5B | 6.4x | +2.13% |
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company's other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $98.5B |
---|---|
Revenue (TTM) | $27.4B |
Shares Outstanding | 1.2B |
Dividend Yield | 3.79% |
Annual Dividend Rate | 3.0000 USD |
Ex-Dividend Date | 12-14-23 |
Pay Date | 12-28-23 |
Beta | 0.24 |
EPS | $4.66 |
Book Value | $17.03 |
P/E Ratio | 17.0x |
Price/Sales (TTM) | 3.6 |
Price/Cash Flow (TTM) | 11.7x |
Operating Margin | 30.16% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.